Arcutis Biotherapeutics Inc Dossier - Source-backed chat

Arcutis Biotherapeutics Inc

ARQTNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.34

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $26.43Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $3.3B

Enterprise Value $3.4B

Shares Outstanding 136.7M diluted

Moat Rating None

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Arcutis Biotherapeutics is successfully transitioning from a single-product launch story into a highly specialized commercial dermatology engine. By repeatedly monetizing its well-understood PDE4 mechanism (roflumilast) across multiple formulations (cream and foam), age groups, and indications, the company is capturing a growing share of the chronic dermatology market. Despite seasonal Q1 headwinds, the company's flagship ZORYVE franchise demonstrated robust 65% year-over-year growth in Q1 2026, reaching $105.4 million in net product sales. Crucially, Arcutis has achieved positive operating cash flow ($2.2 million in Q1 2026), significantly de-risking the equity story by reducing the immediate need for dilutive capital raises. With a completed dermatology salesforce expansion and an ongoing build-out of a dedicated primary care and pediatric sales team, Arcutis is well-positioned to meet its reaffirmed full-year 2026 revenue guidance of $480 million to $495 million.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets8 analysts · as of 18 Aug 2026

Low · most bearish analyst$34.00

Mean target$36.88

High · most bullish analyst$40.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$34.00

The bear case centers on commercial execution risks and high operational spend. If the expansion into primary care and pediatrics fails to drive a meaningful inflection in prescription volumes, the elevated SG&A expenses will pressure margins and delay consistent profitability. Additionally, aggressive payer negotiations could worsen gross-to-net deductions, offsetting unit demand growth. High product concentration on roflumilast leaves the company vulnerable to competitive launches (such as VTAMA or Opzelura) or unexpected safety signals, which would lead to a downward recalibration of long-term peak sales estimates.

Base CaseCentral scenario

$36.88

Matches the consensus mean

The base case assumes Arcutis executes in line with its reaffirmed full-year 2026 net product revenue guidance of $480 million to $495 million, representing 26% to 30% year-over-year growth. ZORYVE remains the leading prescribed branded non-steroidal topical treatment, with gross-to-net rates stabilizing in the 50s. Operating cash flow remains positive throughout 2026, and the company continues to transition toward consistent quarterly GAAP profitability. Pipeline readouts in vitiligo and HS progress as scheduled, maintaining steady investor confidence.

Bull CaseUpside scenario

$40.00

The bull case is driven by rapid market penetration of ZORYVE across its three approved indications, supported by the newly expanded dermatology salesforce and the newly established primary care/pediatric team. Label expansions, such as the potential approval of ZORYVE cream 0.3% down to age 2 (PDUFA date June 29, 2026) and the sNDA submission for infants aged 3 to 24 months, significantly expand the addressable patient population. Under this scenario, gross-to-net deductions improve to the low 50s by year-end, driving operating leverage and accelerating GAAP profitability. Pipeline optionality from ARQ-234 and positive Phase 2 readouts in vitiligo (Q4 2026) and HS (Q1 2027) provide further long-term valuation upside.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong commercial momentum with ZORYVE net product sales growing 65% YoY to $105.4 million in Q1 2026.
Achieved positive operating cash flow of $2.2 million in Q1 2026, reducing dilution risk and self-funding future growth.
Reaffirmed full-year 2026 revenue guidance of $480 million to $495 million, representing robust 26% to 30% growth.
Expanding addressable market through pediatric label expansions and upcoming Phase 2 readouts in vitiligo and HS.

Key Investment Risks

High product concentration with the current equity story almost entirely dependent on roflumilast (ZORYVE).
Elevated operational expenses (SG&A and R&D) could delay consistent GAAP profitability if sales growth slows.
Payer pressure and formulary negotiations could negatively impact gross-to-net sales deductions.
Intense competition in the topical dermatology market from established branded therapies and low-cost generics.

Thesis Invalidation Triggers

ZORYVE net product revenue consistently missing quarterly consensus estimates or falling below the guided 2026 range.
Gross-to-net sales deductions deteriorating significantly above the mid-50s range.
A reversal in operating cash flow back to sustained negative levels, necessitating dilutive equity financing.
Regulatory rejection or significant delays for the pediatric label expansions of ZORYVE.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.